DiNAK Therapeutics

DiNAK Therapeutics is a biotechnology company specializing in the development of precision oncology therapies targeting the DNA damage response (DDR) pathway. The company's primary focus is on creating highly selective small molecule inhibitors that address the limitations of first-generation DDR agents, particularly regarding off-target toxicity. Its lead candidate, DNK-01, is a selective WEE1 inhibitor currently in IND-enabling studies for the treatment of various solid tumors. DiNAK was founded by the former executive team of Zentalis Pharmaceuticals, bringing significant expertise in medicinal chemistry and oncology drug development. The company aims to provide new treatment options for patients with cancers harboring specific genetic vulnerabilities.